Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Revises Product Overstocking Impact With $262 Mil. Medicaid Accrual

Executive Summary

Bristol-Myers Squibb is increasing its estimate of the impact of wholesaler overstocking by $262 mil. to reflect an adjustment to the amount it has set aside for Medicaid rebate payments

You may also be interested in...



SEC inquiry

Bristol "continues to believe that its accounting treatment of domestic wholesaler build-up has been completely appropriate," CEO Peter Dolan declares. The company specifically discussed its treatment of Medicaid accrual rates associated with the wholesaler inventory issues before recording a special charge for that amount in first quarter earnings, Dolan says (1"The Pink Sheet" April 29, p. 15)...

SEC inquiry

Bristol "continues to believe that its accounting treatment of domestic wholesaler build-up has been completely appropriate," CEO Peter Dolan declares. The company specifically discussed its treatment of Medicaid accrual rates associated with the wholesaler inventory issues before recording a special charge for that amount in first quarter earnings, Dolan says (1"The Pink Sheet" April 29, p. 15)...

Bristol Inventory Issues Include High Supply Of Glucophage IR

Bristol-Myers Squibb's new approach to wholesaler inventory levels should help the company capture more of the benefit from product price increases, CEO Peter Dolan suggested during an April 25 earnings conference call

Related Content

UsernamePublicRestriction

Register

PS039728

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel